TY -的T1 Rifampicin-resistant肺结核:what is the best initial empiric regimen in Mumbai, India? JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02182-2016 VL - 50 IS - 1 SP - 1602182 AU - Mullerpattan, Jai Bharat AU - Nikam, Chaitali AU - Sharma, Ujjwal AU - Rodrigues, Camilla AU - Pinto, Lancelot Mark Y1 - 2017/07/01 UR - //www.qdcxjkg.com/content/50/1/1602182.abstract N2 - Multidrug-resistant tuberculosis (MDR-TB), defined as tuberculosis caused by strains of Mycobacterium tuberculosis (MTB) resistant to the two most important antituberculous drugs – isoniazid and rifampicin – carries a poor prognosis, a high mortality rate and treatment success rates as low as 65% [1]. India has the largest burden of MDR-TB worldwide, with an annual incidence of 130 000 patients [2]. Mumbai, a city populated by over 12 million people, is a hotspot for MDR-TB, with reports indicating the proportion of MDR-TB to be as high as 24% in newly diagnosed patients and 41% in previously treated patients with tuberculosis [3].Time is tissue: an effective empiric regimen for multidrug-resistant TB tailored to local epidemiology http://ow.ly/Tzw530c2uoI ER -